Novo Nordisk has launched its groundbreaking weight-loss drug, Wegovy, in India. This semaglutide-based injection promises to help individuals tackle obesity and related heart risks, offering a solution to India's growing health concerns. Available as a once-weekly injection, Wegovy works by mimicking the body's natural GLP-1 hormone, which regulates hunger, reduces cravings, and helps control blood sugar. Clinical trials have shown that Wegovy can result in a 20% body weight loss within 68 weeks, along with a 20% reduction in the risk of major heart problems.

The drug is suitable for adults with a BMI of 30 or higher or a BMI of 27 with weight-related health conditions. It is designed to be used under medical supervision to ensure safety, as some individuals may experience side effects. Wegovy's availability comes at a critical time, as India ranks third in the world for obesity rates, with over 254 million affected.

With a tiered pricing model, Novo Nordisk aims to make Wegovy more accessible, offering the first three doses at Rs 17,345 per month and the full dose at Rs 26,015. While obesity is often viewed as a lifestyle issue, it’s increasingly recognized as a chronic condition that contributes to over 200 diseases, including diabetes, heart disease, and certain cancers. Wegovy represents a shift in the treatment of obesity in India, offering not just a weight loss solution but a comprehensive approach to managing health risks associated with obesity.